We are live on !
Find out more
Commonwealth Equity Services Portfolio holdings
AUM
$79.5B
Turnover
11.02%
1-Year Est. Return
27.1%
This Fund
S&P 500
This Quarter Est. Return
+15.68%
1 Year Est. Return
+27.1%
3 Year Est. Return
+78.53%
5 Year Est. Return
+87.9%
10 Year Est. Return
+281.22%
AUM
$79.5B
AUM Growth
+$7.93B
(+11%)
Cap. Flow
-$643M
Cap. Flow % of AUM
Cap. Flow %
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
16.98%
Holding
4,611
New
312
Increased
1,846
Reduced
2,170
Closed
196
Avg Time Held
5.9
years
Top 10 Avg Time Held
8.7
years
Top 20 Avg Time Held
7.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco NASDAQ 100 ETF
QQQM
|
+$70M |
| 2 |
Putnam Focused Large Cap Value ETF
PVAL
|
+$65.3M |
| 3 |
Fidelity Fundamental Large Cap Growth ETF
FFLG
|
+$50M |
| 4 |
Eli Lilly
LLY
|
+$42.5M |
| 5 |
SpaceX
SPCX
|
+$40.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$122M |
| 2 |
NVIDIA
NVDA
|
+$99.2M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$97.3M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$79.7M |
| 5 |
iShares MSCI USA Quality Factor ETF
QUAL
|
+$69.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 66.62% |
| 2 | Technology | 12.02% |
| 3 | Financials | 4.01% |
| 4 | Industrials | 3.47% |
| 5 | Consumer Discretionary | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4301
CEL-SCI Corp
CVM
$28.3M
| $53.5K | ﹤0.01% |
51,434
+33,812
| +192% | +$74.1K |
2025 Q3
3 quarters
|
|
4302
Broadwind
BWEN
$69.8M
| $53.1K | ﹤0.01% |
+10,994
| New | +$36.4K |
2026 Q2
0 quarters
|
|
4303
Incannex Healthcare Limited Common Stock
IXHL
$32.6M
| $52.8K | ﹤0.01% |
14,029
+1,917
| +16% | +$7K |
2025 Q2
4 quarters
|
|
4304
Commerce.com Inc Series 1
CMRC
$304M
| $52.3K | ﹤0.01% |
17,661
| – | – |
2020 Q3
23 quarters
|
|
4305
Bausch Health
BHC
$2.43B
| $52.2K | ﹤0.01% |
+10,592
| New | +$56.8K |
2026 Q2
0 quarters
|
|
4306
B&G Foods
BGS
$175M
| $51.8K | ﹤0.01% |
13,020
-2,157
| -14% | -$10K |
2013 Q2
52 quarters
|
|
4307
Lexeo Therapeutics
LXEO
$237M
| $51.8K | ﹤0.01% |
11,123
-2,497
| -18% | -$13.5K |
2025 Q2
4 quarters
|
|
4308
MIRA Pharmaceuticals
MIRA
$26.4M
| $50.3K | ﹤0.01% |
53,189
+18,122
| +52% | +$18.3K |
2024 Q4
6 quarters
|
|
4309
Neuphoria Therapeutics
NEUP
$18.8M
| $49K | ﹤0.01% |
11,222
| – | – |
2025 Q4
2 quarters
|
|
4310
Sundial Growers
SNDL
$317M
| $46.4K | ﹤0.01% |
34,363
+273
| +0.8% | +$391 |
2021 Q1
21 quarters
|
|
4311
W&T Offshore
WTI
$587M
| $45.8K | ﹤0.01% |
14,556
+3,656
| +34% | +$13.6K |
2023 Q4
10 quarters
|
|
4312
Gevo
GEVO
$282M
| $45.4K | ﹤0.01% |
30,281
| – | – |
2024 Q4
6 quarters
|
|
4313
Protalix BioTherapeutics
PLX
$207M
| $45.3K | ﹤0.01% |
19,461
| – | – |
2022 Q4
14 quarters
|
|
4314
Microvast
MVST
$192M
| $43.2K | ﹤0.01% |
36,929
+23,000
| +165% | +$35.4K |
2023 Q4
10 quarters
|
|
4315
Protara Therapeutics
TARA
$144M
| $42K | ﹤0.01% |
11,000
| – | – |
2025 Q3
3 quarters
|
|
4316
DELISTED
Esperion Therapeutics
ESPR
| $41.2K | ﹤0.01% |
13,050
-8,000
| -38% | -$22.4K |
2024 Q1
9 quarters
|
|
4317
Voyager Therapeutics
VYGR
$115M
| $41K | ﹤0.01% |
11,704
+400
| +4% | +$1.52K |
2024 Q1
9 quarters
|
|
4318
Genelux
GNLX
$89.6M
| $39.4K | ﹤0.01% |
13,083
-4,000
| -23% | -$11.3K |
2024 Q2
8 quarters
|
|
4319
ALX Oncology
ALXO
$165M
| $38.2K | ﹤0.01% |
+18,451
| New | +$33K |
2026 Q2
0 quarters
|
|
4320
Pennant Park Investment Corp
PNNT
$189M
| $37.7K | ﹤0.01% |
10,863
-36,224
| -77% | -$150K |
2022 Q3
15 quarters
|
|
4321
Orion Office REIT
ONL
$123M
| $36.5K | ﹤0.01% |
12,618
-1,476
| -10% | -$4.04K |
2021 Q4
18 quarters
|
|
4322
Richtech Robotics
RR
$263M
| $36.2K | ﹤0.01% |
17,182
-14,175
| -45% | -$34.4K |
2025 Q3
3 quarters
|
|
|
ABTC
4323
American Bitcoin Corp
ABTC
$579M
| $35.7K | ﹤0.01% |
3,497
+106
| +3% | +$1.62K |
2025 Q4
2 quarters
|
|
4324
AEye
LIDR
$41.9M
| $34.3K | ﹤0.01% |
+23,811
| New | +$43K |
2026 Q2
0 quarters
|
|
4325
Oncolytics Biotech
ONCY
$65.6M
| $33.4K | ﹤0.01% |
35,114
| – | – |
2023 Q4
10 quarters
|
|
Similar funds
Commonwealth Equity Services's Q2 2026 Portfolio in Review
As of Q2 2026, Commonwealth Equity Services held 4,611 positions worth $79.5B, up 11% from $71.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Commonwealth Equity Services's Q2 2026 filing shows 312 new, 1,846 increased, 2,170 reduced and 196 closed positions. Its largest new stake was SpaceX: 238,120 shares worth $40.7M. The largest sale was Apple, an estimated $122M.
By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 66% a quarter earlier, followed by Technology and Financials.
- Commonwealth Equity Services's largest Q2 2026 buy was SpaceX: 238,120 shares worth $40.7M.
- Commonwealth Equity Services added most to Invesco NASDAQ 100 ETF in Q2 2026, an estimated $70M increase.
- Commonwealth Equity Services's biggest Q2 2026 reduction was Apple, cutting an estimated $122M.
- Commonwealth Equity Services fully exited Convergence Long/Short Equity ETF in Q2 2026, selling an estimated $7.88M.
- Commonwealth Equity Services's ten largest holdings make up 17% of its $79.5B portfolio in Q2 2026.
- Commonwealth Equity Services opened 312 new positions and closed 196 in Q2 2026.
- Commonwealth Equity Services's portfolio value rose 11% quarter-over-quarter to $79.5B.
Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.